INT112560

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2003
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 1.27
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (PSMG1) cytoplasm (PSMG1)
Anatomy Link Frequency
platelets 2
blood 1
leukocyte 1
PSMG1 (Homo sapiens)
Pain Link Frequency Relevance Heat
anesthesia 2 50.00 Quite Low
antagonist 1 50.00 Quite Low
agonist 15 25.00 Low Low
aspirin 12 5.00 Very Low Very Low Very Low
Angina 7 5.00 Very Low Very Low Very Low
adenocard 6 5.00 Very Low Very Low Very Low
Inflammation 3 5.00 Very Low Very Low Very Low
cytokine 2 5.00 Very Low Very Low Very Low
withdrawal 1 5.00 Very Low Very Low Very Low
Crohn's disease 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Heart Rate Under Development 65 100.00 Very High Very High Very High
Hemolytic Uremic Syndrome 41 5.00 Very Low Very Low Very Low
Thrombosis 13 5.00 Very Low Very Low Very Low
Coronary Artery Disease 12 5.00 Very Low Very Low Very Low
Stress 7 5.00 Very Low Very Low Very Low
Cv General 3 Under Development 7 5.00 Very Low Very Low Very Low
Disease 6 5.00 Very Low Very Low Very Low
Acute Renal Failure 5 5.00 Very Low Very Low Very Low
Death 4 5.00 Very Low Very Low Very Low
Myocardial Infarction 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: Two types of glycoprotein IIb/IIIa complex antagonists, peptide-mimetic FK633 and abciximab and prostaglandin E(1), significantly prevented platelet loss and the increase in binding of PAC-1, an antibody specific for fibrinogen receptor on activated platelets, during extracorporeal circulation of heparinized blood.
Positive_regulation (increase) of PAC-1 Binding (binding) of in platelets
1) Confidence 0.49 Published 2003 Journal J. Thorac. Cardiovasc. Surg. Section Body Doc Link 12928640 Disease Relevance 0 Pain Relevance 0
As expected, the median values of CD62P expression and PAC-1 binding in patients were significantly lower than in controls only in high responders (p < 0.0001) and intermediate responders (p < 0.0001 and p < 0.02, respectively).


Positive_regulation (values) of PAC-1 Binding (binding) of associated with heart rate under development
2) Confidence 0.11 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.38 Pain Relevance 0
Among the patients, six (11.5%) exhibited both CD62P expression and PAC-1 binding above the 1st quartile of normal (median and IQR: 29.5%, 23.4–42.9%; and 4.4%, 2.3–7.9%, respectively).
Positive_regulation (exhibited) of PAC-1 Binding (binding) of associated with heart rate under development
3) Confidence 0.11 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.27 Pain Relevance 0
In contrast, 23 patients (44.2%) exhibited both CD62P expression and PAC-1 binding below the 1st quartile of normal (median and IQR: 7.8%, 1.8–19.7%; and 0.8%, 0.1–1.7%, respectively) and were defined as high-responders to clopidogrel.
Positive_regulation (exhibited) of PAC-1 Binding (binding) of associated with heart rate under development
4) Confidence 0.11 Published 2009 Journal Thromb J Section Body Doc Link PMC2683811 Disease Relevance 0.34 Pain Relevance 0
An increase in binding of the PAC-1 antibody was detected on leukocyte-bound platelets in whole blood stimulated with Stx2 although no effect was noted on unbound platelets.
Positive_regulation (increase) of PAC-1 in leukocyte Binding (binding) of in blood associated with heart rate under development
5) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2735777 Disease Relevance 0.28 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox